EUVIMEDEUVIMED entdecken
Crossref

Adopting adalimumab combined surgery in the management of moderate to severe hidradenitis suppurativa: Experience from a single medical center in southern Taiwan

Po-Ta Lai iD, Han-Chi Tseng iD

The Journal of Dermatology · 2024

DOI: 10.1111/1346-8138.17375 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Dermatology, 2024. Verfasst von Po-Ta Lai und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan, ROC. Hauptthemen laut MEDLINE: Hidradenitis Suppurativa, Adalimumab, Severity of Illness Index. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: Chang Gung Memorial Hospital Research Program, Taiwan Ministry of Science and Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hidradenitis suppurativa (HS) is a chronic inflammatory disorder primarily affecting the intertriginous and anogenital regions. Guidelines recommend various treatments for HS, including biologic agents like adalimumab for moderate to severe cases. Adalimumab is a type of human monoclonal IgG1 antibody designed to target tumor necrosis factor α . Recent studies have shown the effectiveness of adalimumab, either alone or combined with surgery, in managing HS. We retrospectively analyzed the medical chart of HS patients in a southern Taiwan medical center from 2019 to 2022 and investigated clinical features and treatment response. The institutional review board at Chang Gung Medical Foundation granted approval for the study. We primarily focused on moderate to severely affected patients. One hundred and two clinically diagnosed HS patients participated, with a male‐to‐female ratio of 2:1 and an average age of 31.8 at diagnosis. Among them, 41.2% were in Hurley stage III and 32.4% in stage II. Nineteen patients received excision with pre‐surgical adalimumab; their average age at diagnosis was 31.1, with a gender ratio of 5.3:1. Surgery was most common on the buttocks (68%), axillae (21%), and groin (10%). Excision patients were primarily in advanced stages (Hurley III 94.7%, II 5.3%) with high body mass index. Adalimumab and surgery combined yielded a 68.4% improvement rate, while 15.8% remained stable and 15.8% did not respond as expected. In addition, smoking and obesity were prevalent among patients. Adalimumab showed promising results in moderate to severe HS, with significant improvement observed in our cases. The combination of adalimumab and surgery appeared effective in advanced HS patients with larger involved areas and more tunnels. No severe adverse events were reported. However, our study was limited by its retrospective nature and the lack of a control group. Despite these limitations, our study revealed the benefits of integrating adalimumab with suitable surgical procedures in managing patients experiencing moderate to severe HS in real‐world scenarios.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hidradenitis SuppurativaAdalimumabSeverity of Illness IndexHumansMaleFemaleRetrospective StudiesTaiwanAdultTreatment OutcomeCombined Modality TherapyMiddle AgedYoung Adult

Stichwörter der Autor:innen

adalimumabbiologic treatmenthidradenitis suppurativasurgerysurgical management

Substanzen

Adalimumab

Autor:innen und Institutionen

  • Department of Dermatology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan, ROC.
  • Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Taoyuan, Taiwan, ROC.

ORCID-Profile: Po-Ta Lai, Han-Chi Tseng

Förderung

  • Chang Gung Memorial Hospital Research Program
  • Taiwan Ministry of Science and Technology

Zitieren

APA

Lai, P. T., & Tseng, H. C. (2024). Adopting adalimumab combined surgery in the management of moderate to severe hidradenitis suppurativa: Experience from a single medical center in southern Taiwan. The Journal of Dermatology. https://doi.org/10.1111/1346-8138.17375

Vancouver

Lai PT, Tseng HC. Adopting adalimumab combined surgery in the management of moderate to severe hidradenitis suppurativa: Experience from a single medical center in southern Taiwan. The Journal of Dermatology. 2024. doi:10.1111/1346-8138.17375

BibTeX
@article{Lai2024,
  author = {Lai, Po-Ta and Tseng, Han-Chi},
  title = {Adopting adalimumab combined surgery in the management of moderate to severe hidradenitis suppurativa: Experience from a single medical center in southern Taiwan},
  journal = {The Journal of Dermatology},
  year = {2024},
  doi = {10.1111/1346-8138.17375}
}
Kostenlos starten →